Order Article Reprints

Formica V, Morelli C, Conca V, Calegari MA, Lucchetti J, Dell’Aquila E, Schirripa M, Messina M, Salvatore L, Lo Prinzi F, et al. Irinotecan- vs. Oxaliplatin-Based Doublets in KRAS^G12C-Mutated Metastatic Colorectal Cancer—A Multicentre Propensity-Score-Matched Retrospective Analysis. Cancers. 2023; 15(11):3064. https://doi.org/10.3390/cancers15113064

Formica, Vincenzo, Cristina Morelli, Veronica Conca, Maria Alessandra Calegari, Jessica Lucchetti, Emanuela Dell’Aquila, Marta Schirripa, Marco Messina, Lisa Salvatore, Federica Lo Prinzi, and et al. 2023. "Irinotecan- vs. Oxaliplatin-Based Doublets in KRAS^G12C-Mutated Metastatic Colorectal Cancer—A Multicentre Propensity-Score-Matched Retrospective Analysis" Cancers 15, no. 11: 3064. https://doi.org/10.3390/cancers15113064

Formica, V., Morelli, C., Conca, V., Calegari, M. A., Lucchetti, J., Dell’Aquila, E., Schirripa, M., Messina, M., Salvatore, L., Lo Prinzi, F., Dima, G., Trovato, G., Riondino, S., Roselli, M., Skoulidis, F., Arkenau, H.-T., & Cremolini, C. (2023). Irinotecan- vs. Oxaliplatin-Based Doublets in KRAS^G12C-Mutated Metastatic Colorectal Cancer—A Multicentre Propensity-Score-Matched Retrospective Analysis. Cancers, 15(11), 3064. https://doi.org/10.3390/cancers15113064